A double - blind , randomized , controlled , multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in <font color="blue">patients_3</font> <font color="blue">with_3</font> <font color="blue">chronic_3</font> <font color="blue">heart_3</font> <font color="blue">failure_3</font> <font color="blue">after_3</font> <font color="blue">myocardial_3</font> <font color="blue">infarction_3</font> <font color="blue">._3</font> 
<br>
<br> BACKGROUND We sought to determine the safety and preliminary efficacy of transcatheter intramyocardial administration of myoblasts in <font color="blue">patients_3</font> <font color="blue">with_3</font> <font color="blue">heart_3</font> <font color="blue">failure_3</font> <font color="blue">(_3</font> <font color="blue">HF_3</font> <font color="blue">)_3</font> <font color="blue">._2</font> 
<br> METHODS <font color="blue">MARVEL_1</font> is a randomized placebo - controlled trial of image - guided , catheter - based intramyocardial injection of placebo or myoblasts ( 400 or 800 million ) in <font color="blue">patients_4</font> <font color="blue">with_4</font> <font color="blue">class_4</font> <font color="blue">II_4</font> <font color="blue">to_4</font> <font color="blue">IV_4</font> <font color="blue">HF_4</font> <font color="blue">and_4</font> <font color="blue">ejection_4</font> <font color="blue">fraction_4</font> <font color="blue"><_4</font> <font color="blue">35%_4</font> <font color="blue">._4</font> Primary end points were frequency of serious adverse events ( safety ) and changes in 6-minute walk test and Minnesota Living With HF score ( efficacy ) . <font color="blue">Of_2</font> <font color="blue">330_5</font> <font color="blue">patients_5</font> <font color="blue">intended_5</font> <font color="blue">for_5</font> <font color="blue">enrollment_5</font> <font color="blue">,_5</font> <font color="blue">23_5</font> <font color="blue">were_5</font> <font color="blue">randomized_5</font> <font color="blue">(_5</font> <font color="blue">MARVEL-1_5</font> <font color="blue">)_5</font> <font color="blue">before_3</font> <font color="blue">stopping_3</font> <font color="blue">the_3</font> <font color="blue">study_3</font> <font color="blue">for_3</font> <font color="blue">financial_3</font> <font color="blue">reasons_3</font> <font color="blue">._3</font> 
<br> RESULTS At 6 months , similar numbers of events occurred in each <font color="blue">group_1</font> <font color="blue">:_1</font> <font color="blue">8_1</font> <font color="blue">(_1</font> <font color="blue">placebo_1</font> <font color="blue">)_1</font> <font color="blue">,_1</font> <font color="blue">7_1</font> <font color="blue">(_1</font> <font color="blue">low_1</font> <font color="blue">dose_1</font> <font color="blue">)_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">8_1</font> <font color="blue">(_1</font> <font color="blue">high_1</font> <font color="blue">dose_1</font> <font color="blue">)_1</font> <font color="blue">,_1</font> without deaths . Ventricular tachycardia responsive to amiodarone was more frequent in myoblast - treated patients : 1 ( placebo ) , 3 ( low dose ) , and 4 ( high dose ) . A trend toward improvement in functional capacity was noted in myoblast - treated groups ( Î”6-minute walk test of -3.6 vs + 95.6 vs + 85.5 m [ placebo vs low dose vs high dose ; P = .50 ] ) without significant changes in Minnesota Living With HF scores . 
<br> CONCLUSIONS <font color="blue">In_1</font> <font color="blue">HF_2</font> <font color="blue">patients_2</font> <font color="blue">with_2</font> <font color="blue">chronic_2</font> <font color="blue">postinfarction_2</font> <font color="blue">cardiomyopathy_2</font> <font color="blue">,_2</font> transcatheter administration of myoblasts in doses of 400 to 800 million cells is feasible and may lead to important clinical benefits . Ventricular tachycardia may be provoked by myoblast injection but appears to be a transient and treatable problem . A large - scale outcome trial of myoblast administration in <font color="blue">HF_1</font> <font color="blue">patients_1</font> <font color="blue">with_1</font> <font color="blue">postinfarction_1</font> <font color="blue">cardiomyopathy_1</font> is feasible and warranted .